October 13, 2020 : Issue 1071

DISASTERS AVERTED — Near Miss Case Studies

Best Plan for Patient May Not Be The Recommended Plan

SPECIAL FEATURE: AI & the Future of Diabetes Management

Innovative Artificial Intelligence (AI) Tool Optimizes Care for T2D Patients
Part 3 in a three part series

TOP STORIES — Diabetes News and Research

Common Diabetes Drug Linked To Lower Dementia Rates

The Long-term Cardiovascular Effects of Ertugliflozin in Type 2 Diabetes

MOST POPULAR ARTICLES OF THE MONTH

#1 Vitamin D Deficiency Linked to Painful Diabetic Neuropathy

#2 Pumping Up with Protein: Does This Work for Exercise and Health?

#3 Possible Link Connecting COVID-19 and New-Onset Diabetes

This week we offer you part 3 of our series on the use of AI to select a proper diabetes medication regimen. Your response to the information has been overwhelming, and if the comments we have received are an indication of the desire to have this tool available, it only seems like a matter of time till the GlucosePATH software is available for everyone.

One feature that was commented on is the ability of the software to address comorbidities in selecting medication. This is very important when we look at patient disease states and multiple uses for a single medication.

This week Destiny Funchess, PharmD Candidate, South College School of Pharmacy, has a great article on how the use of a very common diabetes medication can possibly have an effect on reducing the risk of dementia.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Female, type 1 diabetes for 42 years, 58 years of age, lives with husband and dog. The patient has hypoglycemic unawareness. We regularly readjust her treatment plan and have recommended CGM for this patient on numerous occasions. Still, she refuses, stating her dog wakes her up if and when she has hypoglycemia. She called to let us know her dog passed away….

Optimize Clinical Diabetes Management with AI Technology

A new clinical software using artificial intelligence is being used for those with type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs.

In part 3: user testimonials about the experience and exciting findings using the software. A more in-depth examination of the benefits of applying decision-support software in clinical practice.   

One of the most commonly prescribed medications worldwide may have a hidden benefit.

Does Ertugliflozin share the same cardiovascular and renal benefits recently demonstrated by other SGLT-2 Inhibitors?